Literature DB >> 19202446

Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients.

Pieter Gillard1, Evy Vandemeulebroucke, Bart Keymeulen, Jacques Pirenne, Bart Maes, Pieter De Pauw, Yves Vanrenterghem, Daniel Pipeleers, Chantal Mathieu.   

Abstract

BACKGROUND: To compare functional beta-cell mass and insulin sensitivity in insulin-independent pancreas-kidney recipients with that in age- and body mass index-matched nondiabetic kidney recipients and normal controls.
METHODS: All transplant recipients were on maintenance immunosuppression with mycophenolate mofetil and tacrolimus since more than 2.7 years (2.2-3.8 years). Their C-peptide release was measured during a 170-min hyperglycemic clamp, first in absence and then in presence of glucagon. Data were compared with those after glucose stimulation alone. Insulin sensitivity under basal and stimulated conditions was calculated using homeostasis model assessment of insulin resistance and insulin sensitivity index, respectively.
RESULTS: Functional beta-cell mass in pancreas-kidney recipients with systemic venous drainage was reduced, representing, respectively, 63% and 80% of that in healthy controls and kidney recipients. Pancreas-kidney recipients exhibited lower insulin sensitivity than healthy controls (homeostasis model assessment of insulin resistance was 0.8, 0.7-1.1 vs. 0.4, 0.3-0.8; P=0.02 and insulin sensitivity index was 17, 12-24 mg/kg/min per 100 microU/mL vs. 31, 20-38 mg/kg/min per 100 microU/mL; P=0.04).
CONCLUSIONS: Using a hyperglycemic clamp, the functional beta-cell mass in insulin-independent pancreas-kidney recipients was found to be 37% and 20% lower than in healthy controls and nondiabetic kidney recipients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19202446     DOI: 10.1097/TP.0b013e3181928a1c

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset.

Authors:  Fariba Vaziri-Sani; Shilpa Oak; Jared Radtke; Ke Lernmark; Kristian Lynch; Carl-D Agardh; Corrado M Cilio; Asa L Lethagen; Eva Ortqvist; Mona Landin-Olsson; Carina Törn; Christiane S Hampe
Journal:  Autoimmunity       Date:  2010-03-19       Impact factor: 2.815

Review 2.  Recovery of endocrine function after islet and pancreas transplantation.

Authors:  Michael R Rickels
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

3.  {beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants.

Authors:  Michael R Rickels; Rebecca Mueller; Karen L Teff; Ali Naji
Journal:  J Clin Endocrinol Metab       Date:  2010-01-22       Impact factor: 5.958

4.  Beneficial effects of posttransplant dipeptidyl peptidase-4 inhibitor administration after pancreas transplantation to improve β cell function.

Authors:  Hye-Won Jang; Chang Hee Jung; Youngmin Ko; Seong Jun Lim; Hye Eun Kwon; Joo Hee Jung; Hyunwook Kwon; Young Hoon Kim; Sung Shin
Journal:  Ann Surg Treat Res       Date:  2021-08-31       Impact factor: 1.859

5.  Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients.

Authors:  Pieter Gillard; Robert Hilbrands; Ursule Van de Velde; Zhidong Ling; Da Hae Lee; Ilse Weets; Frans Gorus; Christophe De Block; Leonard Kaufman; Chantal Mathieu; Daniel Pipeleers; Bart Keymeulen
Journal:  Diabetes Care       Date:  2013-09-16       Impact factor: 19.112

6.  Long-term effects of pancreas transplant alone on nephropathy in type 1 diabetic patients with optimal renal function.

Authors:  Sung Shin; Chang Hee Jung; Ji Yoon Choi; Hyun Wook Kwon; Joo Hee Jung; Young Hoon Kim; Duck Jong Han
Journal:  PLoS One       Date:  2018-01-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.